Antitumor activity of cytokine-induced killer cells against human lung cancer.
Lung cancer is the leading cause of cancer-related death among men and women in the world. Despite the aggressive treatment with surgery, radiation and chemotherapy, the long term survival for lung cancer patients remains low. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human lung cancer was evaluated in vitro and in vivo. Although CD3(+)CD56(+) CIK cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 98% of NCI-H460 human lung cancer cells, which was determined by the (51)Cr-release assay. In addition, CIK cells at doses of 3 and 30 million cells per mouse inhibited 57% and 77% of NCI-H460 tumor growth in nude mouse xenograft assay, respectively. This study suggests that CD3(+)CD56(+) CIK cells may be used as an adoptive immunotherapy for patients with lung cancer.
Kim
Hwan Mook
HM
Bioevaluation center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Chungbuk 363-883, South Korea.
Lim
Jaeseung
J
Park
Song-Kyu
SK
Kang
Jong Soon
JS
Lee
Kiho
K
Lee
Chang Woo
CW
Lee
Ki Hoon
KH
Yun
Mi-Jung
MJ
Yang
Kyu-Hwan
KH
Han
Gyoonhee
G
Kwon
Soon Woo
SW
Kim
Youngsoo
Y
Han
Sang-Bae
SB
D000818:Animals; D017252:CD3 Complex / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D051379:Mice
D017252:CD3 Complex; D019002:CD56 Antigen; D007376:Interleukin-2